Tatsuya Minami

List of Publications by Year in descending order

30 papers	1,178 citations	623734 14 h-index	454955 30 g-index
30 all docs	30 docs citations	30 times ranked	2204 citing authors

#	Article	IF	Citations
1	Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. Journal of Hepatology, 2015, 63, 131-140.	3.7	538
2	The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 1272-1273.	3.7	79
3	Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. Journal of Hepatology, 2019, 70, 78-86.	3.7	71
4	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 473-485.	3.7	62
5	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut, 2022, 71, 593-604.	12.1	62
6	DNA Methylation Regulates Placental Lactogen I Gene Expression. Endocrinology, 2001, 142, 3389-3396.	2.8	61
7	Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Scientific Reports, 2019, 9, 10663.	3.3	57
8	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. Journal of Gastroenterology, 2020, 55, 227-243.	5.1	29
9	Hepatic IRS1 and ÃŸ-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. Journal of Gastroenterology, 2018, 53, 1261-1275.	5.1	25
10	Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e111662.	2.5	24
11	Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology, 2013, 48, 254-268.	5.1	21
12	Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 921-928.	2.8	18
13	Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (United States), 2015, 94, e901.	1.0	16
14	Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Liver Cancer, 2021, 10, 309-319.	7.7	16
15	Comparison of improved prognosis between hepatitis Bâ€•and hepatitis Câ€•related hepatocellular carcinoma. Hepatology Research, 2015, 45, E99-E107.	3.4	15
16	Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. Hepatology Research, 2016, 46, 259-268.	3.4	13
17	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. Journal of Gastroenterology, 2021, 56, 456-469.	5.1	11
18	Slight elevation of highâ€•sensitivity <scp>C</scp>â€•reactive protein to predict recurrence and survival in patients with early stage hepatitis <scp>C</scp>â€•related hepatocellular carcinoma. Hepatology Research, 2015, 45, 645-655.	3.4	10

#	Article	IF	Citations
19	Spontaneous clearance of serum hepatitis <scp>C</scp> virus <scp>RNA</scp> during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis <scp>C</scp>. Hepatology Research, 2014, 44, E32-7.	3.4	8
20	A Novel Non-invasive Method for Predicting Liver Fibrosis by Quantifying the Hepatic Vein Waveform. Ultrasound in Medicine and Biology, 2019, 45, 2363-2371.	1.5	6
21	Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. PLoS ONE, 2020, 15, e0231836.	2.5	6
22	Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor. Liver International, 2021, 41, 2233-2234.	3.9	6
23	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). Journal of Gastroenterology, 2022, 57, 587-597.	5.1	5
24	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE, 2018, 13, e0200943.	2.5	4
25	Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. Hepatology Research, 2019, 49, 453-461.	3.4	4
26	Improved prognosis of hepatitis Câ€related hepatocellular carcinoma in the era of directâ€acting antivirals. Hepatology Communications, 2022, 6, 2496-2512.	4.3	4
27	Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments. Journal of Vascular and Interventional Radiology, 2021, 32, 869-877.	0.5	3
28	Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics. PLoS ONE, 2021, 16, e0259641.	2.5	2
29	Chronological change in alphaâ€fetoprotein levels in hepatocellular carcinoma after eradication of hepatitis C virus. Liver International, 2020, 40, 2305-2306.	3.9	1
30	Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan. Journal of Hepatology, 2022, , .	3.7	1